Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

International Journal of Antimicrobial Agents

Volumn 35, Issue 1, 2010, Pages 3-12

  Beibei, Liang ^a   Yun, Cai ^a   Mengli, Chen ^a   Nan, Bai ^a   Xuhong, Yu ^a   Rui, Wang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Gram positive infections; Linezolid; Meticillin resistant Staphylococcus aureus; MRSA; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; DICLOXACILLIN; LINEZOLID; OXACILLIN; VANCOMYCIN;

ANEMIA; BACTEREMIA; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; MEDLINE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SHORT SURVEY; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG TOXICITY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 70849093801     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.013     Document Type: Short Survey

References (45)

1. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
2. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
3. Wang F., Zhu D.M., Hu F.P., and Zhang Y.Y. Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 7 (2001) 117-120
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
5. Hope R., Livermore D.M., Brick G., Lillie M., and Reynolds R. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62 Suppl. 2 (2008) ii65-ii74
6. Lodise Jr. T.P., and McKinnon P.S. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 27 (2007) 1001-1012
7. Shorr A.F., Tabak Y.P., Gupta V., Johannes R.S., Liu L.Z., and Kollef M.H. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 10 (2006) R97
8. Gould F.K., Brindle R., Chadwick P.R., Fraise A.P., Hill S., Nathwani D., et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63 (2009) 849-861
9. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1670-1673
10. Wong S.S., Ng T.K., and Yam W.C. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 36 (2000) 261-268
11. Zurenko G.E., Yagi B.H., Schaadt R.D., Allison J.W., Kilburn J.O., Glickman S.E., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40 (1996) 839-845
12. Shinabarger D.L., Marotti K.R., Murray R.W., Lin A.H., Melchior E.P., Swaney S.M., et al. Mechanism of action of oxazolidinones: effect of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 41 (1997) 2132-2136
13. Jones R.N., Ballow C.H., Biedenbach D.J., and ZAPS Study Group Medical Centers. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis 40 (2001) 59-66
14. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 43 (2002) 65-73
15. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066
16. Gee T., Ellis R., Marshall G., Andrews J., Ashby J., and Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45 (2001) 1843-1846
17. Falagas M.E., Siempos I.I., and Vardakas K.Z. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8 (2008) 53-66
18. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
19. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998) 609-613
20. Li Z., Willke R.J., Pinto L.A., Rittenhouse B.E., Rybak M.J., Pleil A.M., et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 21 (2001) 263-274
21. Li J.Z., Willke R.J., Rittenhouse B.E., and Glick H.A. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 22 (2002) 45S-54S
22. Willke R.J., Glick H.A., Li J.Z., and Rittenhouse B.E. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int J Technol Assess Health Care 18 (2002) 540-554
23. Li J.Z., Willke R.J., Rittenhouse B.E., and Rybak M.J. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 4 (2003) 57-70
24. Itani K.M., Weigelt J., Li J.Z., and Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 26 (2005) 442-448
25. McKinnon P.S., Sorensen S.V., Liu L.Z., and Itani K.M. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40 (2006) 1017-1023
26. Patanwala A.E., Erstad B.L., and Nix D.E. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 23 (2007) 185-193
27. Deville J.G., Adler S., Azimi P.H., Jantausch B.A., Morfin M.R., Beltran S., et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatr Infect Dis J 22 9 Suppl. (2003) S158-S163
28. Jantausch B.A., Deville J., Adler S., Morfin M.R., Lopez P., Edge-Padbury B., et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatr Infect Dis J 22 9 Suppl. (2003) S164-S171
29. Weigelt J., Kaafarani H.M., Itani K.M., and Swanson R.N. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188 (2004) 760-766
30. Yogev R., Patterson L.E., Kaplan S.L., Adler S., Morfin M.R., Martin A., et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 22 9 Suppl. (2003) S172-S177
31. Grudinina S.A., Zubkov M.M., Krotova L.A., Kurdiukova IuP, Kutsenko M.A., Marinin V.F., et al. Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study. Antibiot Khimioter 47 (2002) 12-17 [in Russian]
32. Jaksic B., Martinelli G., Perez-Oteyza J., Hartman C.S., Leonard L.B., and Tack K.J. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42 (2006) 597-607
33. Sharpe J.N., Shively E.H., and Polk Jr. H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 (2005) 425-428
34. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002) 1481-1490
35. Rubinstein E., Cammarata S., Oliphant T., Wunderink R., and Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32 (2001) 402-412
36. Kaplan S.L., Deville J.G., Yogev R., Morfin M.R., Wu E., Adler S., et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 22 (2003) 677-686
37. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
38. Kohno S., Yamaguchi K., Aikawa N., Sumiyama Y., Odagiri S., Aoki N., et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60 (2007) 1361-1369
39. Lin D.F., Zhang Y.Y., Wu J.F., Wang F., Zheng J.C., Miao J.Z., et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 32 (2008) 241-249
40. Wilcox M.H., Tack K.J., Bouza E., Herr D.L., Ruf B.R., Ijzerman M.M., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48 (2009) 203-212
41. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25 (2003) 980-992
42. Wunderink R.G., Mendelson M.H., Somero M.S., Fabian T.C., May A.K., Bhattacharyya H., et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134 (2008) 1200-1207
43. Kuter D.J., and Tillotson G.S. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 21 (2001) 1010-1013
44. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J., et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
45. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulis G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208